Recursion Pharmaceuticals(RXRX)
$2.45-0.27 (-9.93%)
RXRX
Recursion Pharmaceuticals financials statements
$2.45
At close:-0.27 (-9.93%)
Want to see RXRX full AI Analyst Report?
Recursion Pharmaceuticals (RXRX) Income Statement
4,728 Followers
Recursion Pharmaceuticals Income Statement
Last quarter (Q3 2026), Recursion Pharmaceuticals's total revenue was $18.55M, an increase of 258.49% from the same quarter last year. In Q3, Recursion Pharmaceuticals's net income was $-119.04M. See Recursion Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 74.68M | $ 58.84M | $ 43.88M | $ 39.68M | $ 10.00M | |
| $ -46.27M | $ 13.60M | $ 1.29M | $ -8.59M | $ 10.00M | |
| $ 601.86M | $ 492.61M | $ 351.35M | $ 237.13M | $ 192.78M | |
| Depreciation and Amortization | $ 83.70M | $ 36.49M | $ 24.40M | $ 11.76M | $ 8.40M |
| $ -559.38M | $ -426.72M | $ -307.63M | $ -227.66M | $ -175.12M | |
| $ -648.13M | $ -479.00M | $ -350.06M | $ -245.73M | $ -182.78M | |
| $ 3.24M | $ 14.22M | $ 17.93M | $ 6.25M | $ -3.70M | |
| $ -644.89M | $ -464.79M | $ -332.13M | $ -239.48M | $ -186.48M | |
| $ -644.76M | $ -463.66M | $ -328.07M | $ -239.48M | $ -186.48M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.44 | $ -1.69 | $ -1.58 | $ -1.36 | $ -1.05 |
| Diluted EPS | $ -1.44 | $ -1.69 | $ -1.58 | $ -1.36 | $ -1.05 |
| Weighted Average Shares Outstanding | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M |
| Weighted Average Shares Outstanding (Diluted) | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M |
Currency in USD

